Type 1 & Type 2
Diabetes
Quantifying active beta-cell biology to guide diagnosis, monitoring, and therapeutic response.
The First Molecular Platform Built for Disease Interception.
Kihealth Labs is developing next-generation molecular diagnostics that detect disease at its earliest biological stages through proprietary liquid biopsy technology, advanced biomarker science, and AI-powered clinical intelligence.
The Earlier We Detect Disease, the More Lives We Can Change.
Diabetes and metabolic disease often develop silently for years before symptoms appear. By the time conventional diagnostic tests identify disease, irreversible cellular damage may already have occurred. Kihealth Labs is developing molecular diagnostics designed to detect disease earlier — when intervention has the greatest potential to improve outcomes.
A Global Health Crisis Demands Earlier Detection
Diabetes and metabolic disease have become one of the greatest healthcare challenges of our time. Disease often progresses silently for years before traditional clinical tests identify a problem. Kihealth is developing molecular diagnostics designed to detect disease earlier — when intervention has the greatest opportunity to improve long-term outcomes.
537M
Adults living with diabetes worldwide
A global health crisis affecting every region and population.
783M
Projected to have diabetes by 2045
Without earlier detection, prevalence will continue to rise sharply.
$1T+
Spent globally each year on diabetes care
The economic weight of late-stage disease continues to climb.
1B+
People living with obesity worldwide
A leading driver of metabolic dysfunction and cardiometabolic disease.
96M
Americans have prediabetes — most unaware
Silent progression continues for years without clinical signs.
Up to 90%
Of Type 2 diabetes may be preventable
Earlier intervention and lifestyle modification can change trajectories.
Years
Before symptoms appear
Beta-cell dysfunction and molecular changes begin long before diagnosis.
Recognized as the American Diabetes Association's 2025 Innovation of the Year
Kihealth was honored with the Innovation of the Year Award at the 2025 American Diabetes Association Scientific Sessions, recognizing our pioneering work in developing next-generation blood-based diagnostics for the earliest detection of metabolic disease. This award reflects the scientific innovation, clinical potential, and transformative impact of the Intercept IQ™ platform and reinforces Kihealth's position as a leader in precision, preventative medicine.
Who We Are
Building the Future of Preventive Medicine Through Molecular Intelligence
Kihealth is a precision molecular intelligence company advancing the future of healthcare by transforming how disease is predicted, detected, monitored, and prevented.
By integrating proprietary multi-omic science, molecular diagnostics, artificial intelligence, and advanced clinical data, we are developing technologies that reveal disease biology long before traditional symptoms appear—empowering clinicians to make earlier, more informed decisions that improve patient outcomes.
At the heart of our innovation is the Intercept IQ™ Platform—our proprietary molecular intelligence platform that combines cell-free DNA, epigenetics, gene expression, proteomics, clinical biomarkers, and predictive analytics into a unified ecosystem for precision medicine.
Powered by Ki Intelligence™, our proprietary molecular intelligence engine, the platform continuously integrates molecular, clinical, and longitudinal patient data to identify biological patterns, quantify disease risk, generate actionable insights, and support personalized clinical decision-making.
Today, these technologies power our growing portfolio of molecular diagnostics—including Beta Intercept™, Onco Intercept™, and Neuro Intercept™—while establishing the foundation for the next generation of disease interception, precision therapeutics, companion diagnostics, population health, and predictive healthcare.
Our mission is simple: detect disease earlier, enable smarter intervention, and help people live healthier, longer lives.
Why We Exist
Healthcare has long focused on treating disease after symptoms appear. We believe the future lies in understanding disease at the molecular level before irreversible damage occurs.
By combining molecular intelligence with clinical insight, Kihealth is helping shift medicine from reactive treatment to proactive prevention, giving physicians the tools to identify risk earlier, personalize care, monitor disease progression, and improve outcomes across every stage of the patient journey.
Our Vision
To become the world's leading molecular intelligence company, building the technologies that redefine preventive medicine and empower healthier lives through earlier detection, smarter intervention, and precision healthcare.
The Platform
Powering the Future of Precision Healthcare Through Molecular Intelligence
Kihealth combines advanced molecular science, artificial intelligence, and clinical intelligence into a unified technology ecosystem that enables earlier disease detection, more personalized care, and better health outcomes. Our integrated platform transforms complex biological data into actionable clinical insights that support physicians, researchers, healthcare systems, and life science partners.
01
The Foundation of Our Molecular Intelligence Ecosystem
Intercept IQ™ Platform
Our proprietary multi-omic molecular intelligence platform integrates cell-free DNA, epigenetics, gene expression, proteomics, clinical biomarkers, laboratory science, and advanced analytics into a single technology framework designed to accelerate biomarker discovery, disease interception, and precision medicine.
02
The Molecular Intelligence Engine
Ki Intelligence™
Our proprietary artificial intelligence engine continuously integrates molecular, clinical, and longitudinal patient data to identify biological patterns, quantify disease risk, generate predictive insights, and support more informed clinical decision-making across every stage of patient care.
03
Earlier Detection Through Advanced Biology
Precision Molecular Diagnostics
We develop highly sensitive blood-based molecular diagnostics that detect disease-related biological changes before conventional clinical methods, enabling physicians to identify risk earlier, intervene sooner, and monitor patient health more effectively.
04
Validating Innovation Through Evidence
Clinical Research & Translational Science
Working alongside leading academic medical centers, healthcare systems, and research institutions, we generate robust analytical and clinical evidence through prospective studies, translational research, and real-world validation to advance the future of precision medicine.
05
Personalized Care Through Molecular Insight
Precision Medicine
By integrating molecular biology with advanced clinical intelligence, we provide physicians with disease-specific insights that support individualized risk assessment, personalized treatment strategies, therapeutic monitoring, and longitudinal patient management.
06
One Platform. Unlimited Disease Applications.
Scalable Multi-Disease Platform
The Intercept IQ™ platform is designed to scale across multiple disease areas—including diabetes, metabolic disease, oncology, neurodegenerative disorders, and future indications—providing a common molecular intelligence foundation for the next generation of precision healthcare technologies.
The Problem
The Metabolic Disease Crisis
Metabolic disease is one of the largest and fastest-growing healthcare challenges in the world — yet most patients are identified only after significant, often irreversible biological damage has already occurred.
- Stage 01
Healthy Metabolism
Insulin signaling intact. Glucose tightly regulated by a responsive, fully functional pancreas.
—Baseline biology
- Stage 02
Insulin Resistance
Cells become less responsive to insulin. Beta cells compensate by overproducing.
1 in 3U.S. adults with prediabetes· CDC
- Stage 03
Beta Cell Stress
Chronic overproduction strains pancreatic islet cells long before any symptom appears.
~80%of prediabetes goes undiagnosed· CDC
- Stage 04
Beta Cell Death
Cellular apoptosis begins. Pancreatic function silently and irreversibly erodes.
Yearsof damage before clinical detection
- Stage 05
Prediabetes
Glucose dysregulation emerges. The disease is now measurable — and still reversible.
537Mpeople living with diabetes globally· IDF
- Stage 06
Type 2 Diabetes
Clinical thresholds are crossed. Diagnosis is confirmed, often years too late.
240Mliving with undiagnosed diabetes· IDF
- Stage 07
Complications
Cardiovascular, renal, neurological, and retinal injury compound across the body.
$1T+estimated annual global cost of diabetes
What if we could evaluate disease biology earlier — long before this damage becomes irreversible?
That is the Kihealth mission
At the center of metabolic disease — the beta cell.
The health of a single cell type — the pancreatic beta cell — defines whether a patient stays metabolically well, or doesn't.
What We Measure
We measure the biology behind disease — not just its downstream effects. Biomarker testing paired with analytical intelligence reveals active biological processes conventional tests may miss.
Pancreatic islet · immunofluorescence
01
First-in-Class
Beta-Cell Death
Kihealth detects molecular signals of insulin-producing beta-cell loss — measuring the earliest biological event in metabolic disease, before glucose ever shifts.
We are the first to measure this reliably from a single blood sample, making the invisible progression of disease visible and actionable.
02
Beta-Cell Function
How well the remaining beta cells produce and release insulin.
03
Insulin Resistance
How the body responds to insulin — and where resistance begins.
04
Disease Trajectory
Biomarkers over time, integrated into a view of risk and progression.
From a single blood sample to deeper biological insight.
Helping physicians, researchers and therapeutic developers see what is happening beneath the surface of disease.
One draw · many signals
From Blood Sample to Biological Intelligence
Every Kihealth Labs result begins with a simple blood draw and progresses through a highly advanced molecular workflow designed to preserve biological integrity, quantify beta-cell injury, and transform complex molecular signals into clinically actionable intelligence.
- 01
Patient Evaluation
Clinical indication and informed consent
- 02
Blood Collection
Single standard venous draw
- 03
Plasma Preparation
Centrifugation and plasma isolation
- 04
Cell-Free DNA Extraction
Isolation of circulating cfDNA from plasma
- 05
Bisulfite-Free Methylation Analysis
Preserves fragile cfDNA and methylation signal
- 06
Droplet Digital PCR
Bio-Rad platform for absolute quantification
- 07
Ki Intelligence AI Analysis
Intercept IQ™ contextual interpretation
- 08
Clinical Report
Actionable, longitudinal output
Minimally Invasive
Simple blood draw
Highly Precise
Beta-cell-specific detection
Early Insight
Detects change before symptoms
Clinically Actionable
Real data. Real decisions.
Longitudinal Value
Track. Monitor. Intervene.
The Science of Earlier Detection
The Window of Opportunity for Early Intervention
Beta-cell death increases first. Functional beta-cell mass remains preserved. HbA1c stays normal. This creates a unique window where Kihealth enables earlier detection and intervention — before irreversible loss occurs.
HbA1c
Late Marker of Glycemic Dysfunction
Stable early, rising sharply only once significant beta-cell loss has occurred.
Functional Beta-Cell Mass
Insulin-Producing Capacity
Largely preserved through the window of opportunity, then declines once clinical dysfunction begins.
% Demethylated INS cfDNA
Direct Measurement of Beta-Cell Death
★ Kihealth Signal
Rises first — peaking inside the window — then declines as the at-risk reserve is depleted.
Traditional Biomarkers Remain Stable
HbA1c and glucose often stay within the normal range while silent beta-cell injury is already underway.
Kihealth Detects Active Beta-Cell Death
Demethylated INS cfDNA rises as beta cells undergo apoptosis — a direct, earlier molecular signal.
Intervene Before Irreversible Loss
Earlier detection opens the window to preserve functional beta-cell mass before substantial loss has occurred.
The Biological Progression
Where disease begins — and where Kihealth intercepts.
The Kihealth Window
1–5 years before symptoms
Molecular biomarkers reveal disease biology while it is still actionable — long before clinical symptoms appear.
- Stage 01Healthy Biology
- Stage 02Cellular Stress
- Stage 03Beta Cell Injury
- Stage 04Molecular Biomarkers
- Stage 05Clinical Symptoms
- Stage 06Traditional Diagnosis
Kihealth detection window
Conventional diagnostics
The Intercept IQ™ Platform
A next-generation multi-omic diagnostic platform integrating molecular biology, advanced laboratory technologies, artificial intelligence, and longitudinal clinical data — to detect disease earlier and enable precision medicine across multiple disease areas.
Intercept IQ™ is the scientific engine behind every Kihealth diagnostic program. Rather than relying on a single biomarker, the platform integrates multiple biological signals, advanced molecular technologies, and continuously expanding clinical datasets to identify disease at its earliest biological stages.
ARCHITECTURE
A connected ecosystem of biological intelligence.
Every technology pillar feeds a shared molecular intelligence layer — biological signals flow inward, and validated diagnostic insight flows outward across every Kihealth disease program.
01
Multi-Omic Biomarker Discovery
Integrated signal across genomics, epigenomics, and proteomics to reveal early disease biology.
02
Cell-Free DNA Analysis
Ultra-sensitive detection of circulating molecular fragments released by stressed and damaged tissues.
03
Epigenetic Biomarkers
Methylation and chromatin signatures that capture disease state before genetic mutation.
04
Gene Sequencing
Targeted and whole-genome sequencing to resolve variant biology at clinical grade.
05
Digital PCR & Proteomics
Absolute quantification of low-abundance nucleic acid and protein biomarkers.
06
AI & Machine Learning
Models trained on multi-modal biological signal to translate complexity into clinical risk.
07
Longitudinal Clinical Data
Multi-year outcomes linked to molecular readouts across diverse patient populations.
08
Predictive Disease Modeling
Real-world evidence fused with molecular biology to forecast disease trajectory.
Biological signals flow inward from every pillar into a shared molecular intelligence layer
CORE TECHNOLOGIES
A stack engineered for early biological signal.
Fourteen integrated technology domains — spanning wet-lab, molecular, computational, and clinical data science — combined into a single interception platform.
Multi-Omics
Cell-Free DNA
Epigenetics
Transcriptomics
Proteomics
Gene Sequencing
Digital PCR
Molecular Biology
Bioinformatics
Artificial Intelligence
Machine Learning
Predictive Analytics
Clinical Data Integration
Real-World Evidence
WHAT MAKES IT DIFFERENT
Why Intercept IQ™ is different
Built for interception.
Designed to compound.
Intercept IQ™ is architected around one principle: the earlier disease biology can be seen, the more medicine can do. Every layer of the platform — biological, data, and clinical — strengthens with every study and every patient.
Interception, not confirmation
Engineered to detect disease biology at its earliest actionable stage — years before conventional diagnosis.
Multi-layer biological signal
Fuses genomic, epigenomic, proteomic, and cell-free signals instead of relying on any single biomarker.
Continuously learning
Every clinical study, dataset, and real-world outcome strengthens the models and expands biological insight.
Scalable across disease areas
One platform architecture spanning diabetes, metabolic disease, oncology, neurodegeneration, and beyond.
Disease Programs
Where our platform is being applied.
Kihealth Labs is advancing molecular diagnostics across a portfolio of diseases where earlier detection can meaningfully change patient outcomes.
Early Intervention
Prediabetes
Detecting metabolic dysfunction years before conventional markers become abnormal.
MASH & Beyond
Metabolic Disease
Molecular readouts of hepatic and systemic metabolic injury for earlier clinical action.
Early Detection Research
Pancreatic Cancer
Investigating tissue-of-origin signals to surface pancreatic malignancy at treatable stages.
Exploratory Program
Neurodegenerative Disease
Extending the platform to neurologic tissue signals for pre-symptomatic detection.
One platform.
Many applications.
Intercept IQ™ generates biological intelligence across prevention, clinical care, therapeutic innovation, and population health.
Population Screening
Identify metabolic risk earlier across communities and systems.
Clinical Trials
Stratify and monitor patient populations for therapeutic development.
GLP-1 Monitoring
Quantify biological response to GLP-1 and metabolic therapies.
Functional & Longevity
Evaluate metabolic health through a root-cause clinical lens.
Pediatric Diabetes
Support pediatric Type 1 diabetes screening and monitoring.
Employer Programs
Power workforce health and preventative initiatives at scale.
Built on academic rigor.
Multi-center cohorts, leading institutions, and a growing body of peer-reviewed evidence — the foundation beneath every result Kihealth returns.
View the full validation dashboard10+
Academic partners
7+
Clinical sites
1,200+
Patient samples
4
Publications & posters
A trusted network of leading institutions.
Multi-center collaborations with the academic and clinical organizations defining the future of metabolic health.
From Yale discovery to global platform.
Kihealth's science traces directly to foundational Type 1 diabetes research at Yale — translated, protected, and engineered into a commercial diagnostics platform.
- YaleFoundational researchBeta cell cfDNA biology — Herold Lab
- DiscoveryScientific platformMethylation atlas validated
- IPPatent protection7+ patent assets secured
- ClinicalMulti-center validationTEDDY · DAISY · Nemours · UF
- TodayCommercial platformIntercept IQ™ in market
- GlobalExpansionPartnerships & programs worldwide
Disease interception, years earlier.
Partner with Kihealth to bring metabolic intelligence to clinicians, pharmaceutical programs, and the patients waiting on better answers.